title: The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis.
abstract: The proto-oncogene RAS, coding for a 21 kDa protein (p21), is mutated in 20% of lung cancer. However, the literature remains controversial on its prognostic significance for survival in lung cancer. We performed a systematic review of the literature with meta-analysis to assess its possible prognostic value on survival. Published studies on lung cancer assessing prognostic value of RAS mutation or p21 overexpression on survival were identified by an electronic search. After a methodological assessment, we estimated individual hazard ratios (HR) estimating RAS protein alteration or RAS mutation effect on survival and combined them using meta-analytic methods. In total, 53 studies were found eligible, with 10 concerning the same cohorts of patients. Among the 43 remaining studies, the revelation method was immunohistochemistry (IHC) in nine and polymerase chain reaction (PCR) in 34. Results in terms of survival were significantly pejorative, significantly favourable, not significant and not conclusive in 9, 1, 31, 2, respectively. In total, 29 studies were evaluable for meta-analysis but we aggregated only the 28 dealing with non-small-cell lung cancer (NSCLC) and not the only one dealing with small-cell-lung cancer (SCLC). The quality scores were not statistically significantly different between studies with or without significant results in terms of survival, allowing us to perform a quantitative aggregation. The combined HR was 1.35 (95% CI: 1.16-1.56), showing a worse survival for NSCLC with KRAS2 mutations or p21 overexpression and, particularly, in adenocarcinomas (ADC) (HR 1.59; 95% CI 1.26-2.02) and in studies using PCR (HR 1.40; 95% CI 1.18-1.65) but not in studies using IHC (HR 1.08; 95% CI 0.86-1.34). RAS appears to be a pejorative prognostic factor in terms of survival in NSCLC globally, in ADC and when it is studied by PCR.
authors.affiliation: Department of Intensive Care and Thoracic Oncology, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Belgium. celine.mascaux@bordet.be
authors.forename: C
authors.initials: C
authors.lastname: Mascaux
authors.forename: N
authors.initials: N
authors.lastname: Iannino
authors.forename: B
authors.initials: B
authors.lastname: Martin
authors.forename: M
authors.initials: M
authors.lastname: Paesmans
authors.forename: T
authors.initials: T
authors.lastname: Berghmans
authors.forename: M
authors.initials: M
authors.lastname: Dusart
authors.forename: A
authors.initials: A
authors.lastname: Haller
authors.forename: P
authors.initials: P
authors.lastname: Lothaire
authors.forename: A-P
authors.initials: AP
authors.lastname: Meert
authors.forename: S
authors.initials: S
authors.lastname: Noel
authors.forename: J-J
authors.initials: JJ
authors.lastname: Lafitte
authors.forename: J-P
authors.initials: JP
authors.lastname: Sculier
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics*; D011905:Genes, ras; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics*; D009154:Mutation; D011379:Prognosis; D000090063:Proto-Oncogene Mas; D012680:Sensitivity and Specificity; D015996:Survival Rate